NASDAQ OMX Group Inc held preliminary talks with Carlyle Group LP about going private before the discussions broke down on price, according to a person with direct knowledge of the matter.
The talks were initiated by Carlyle chief financial officer Adena Friedman, who left NASDAQ in 2011 as chief financial officer and head of corporate strategy, said the person, who asked not to be identified because the meetings were private.
NASDAQ surged 3.6 percent to a four-year high of US$30.53 at 1:25pm in New York on Monday. The shares gained as much as 9.1 percent, the biggest intraday advance since August 2011.
“Why NASDAQ sells is because it creates shareholder value,” Rich Repetto, an exchange analyst at Sandler O’Neill & Partners LP in New York, said in a phone interview. “If they could sell it at US$35 or US$40, I think they’d be pretty happy ... If they can sell and create more value than what they think they can by just operating organically, then it’s the board’s duty to look at those options.”
NASDAQ OMX spokesman Rob Madden declined to comment, saying the company does not speak about “rumors or speculation.” Carlyle’s spokesman Randy Whitestone also declined to comment. The talks were reported earlier by Fox Business Network.
NASDAQ chief executive officer Robert Greifeld is reorganizing business units and reducing expenses as revenue from trading shrinks around the world. The exchange is expanding into derivatives, setting up a new London-based market and buying a 25 percent stake in a Dutch alternative trading system focused on stocks and equity derivatives.
The company reported fourth-quarter earnings that beat analysts’ estimates on Jan. 31 after cutting costs. Profit in the three months ended Dec. 31 jumped to US$85 million, or US$0.50 a share, from US$82 million, or US$0.45, in the fourth quarter of 2011.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
‘LITTLE CHOICE’: The airline said it expected only about 8,000 of its 29,000 employees to be working by next month, but hoped to have 21,000 in the next two years Qantas Airways Ltd plans to cut at least 6,000 jobs and keep 15,000 more workers on extended furloughs as Australia’s largest airline tries to survive the coronavirus pandemic. Qantas yesterday announced a plan to reduce costs by billions of dollars and raise fresh capital. The plan includes grounding 100 planes for a year or more and immediately retiring its six remaining Boeing Co 747 planes. Chief executive Alan Joyce said the airline has to become smaller as it braces for several years of much lower revenues. He said the furloughed workers faced a long interruption to their airline careers. “The actions that we’re taking
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price